Previous work on Relative Clause attachment has overlooked a crucial grammatical distinction across both the languages and structures tested: the selective availability of Pseudo Relatives. We reconsider the literature in light of this... more
Previous work on Relative Clause attachment has overlooked a crucial grammatical distinction across both the languages and structures tested: the selective availability of Pseudo Relatives. We reconsider the literature in light of this observation and argue that, all else being equal, local attachment is found with genuine Relative Clauses and that non-local attachment emerges when their surface identical imposters, Pseudo Relatives, are available. Hence, apparent cross-linguistic variation in parsing preferences is reducible to grammatical factors. The results from two novel experiments in Italian are presented in support of these conclusions.
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The... more
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.
The development of effective and safe drugs for a growing Alzheimer disease population is an increasing need at present. Both experimental and clinical evidence support a beneficial effect of proline-rich polypeptides in a number of... more
The development of effective and safe drugs for a growing Alzheimer disease population is an increasing need at present. Both experimental and clinical evidence support a beneficial effect of proline-rich polypeptides in a number of neurodegenerative diseases, including Alzheimer disease. Experimental data have shown that proline-rich polypeptides isolated from bovine neurohypophisis possess neuroprotective and neuromodulatory properties in mice with aluminum neurotoxicosis or neuronal damage caused by venoms and toxins. Proline-rich polypeptides from ovine colostrums, so called Colostrinin, have been shown to produce cognitive improvement in an experimental model and in patients with Alzheimer disease. However, the precise mechanism underlying the neuroprotective action of proline-rich polypeptides is not very well established. Moreover, studies pointing at a neuroprotective effect of proline-rich polypeptides from bovine neurohypophisis in humans have not been reported thus far. T...
This paper covers the canonical genetic algorithm as well as more experimental forms of genetic algorithms, including parallel island models and parallel cellular genetic algorithms. The theoretical foundations of genetic algorithms are... more
This paper covers the canonical genetic algorithm as well as more experimental forms of genetic algorithms, including parallel island models and parallel cellular genetic algorithms. The theoretical foundations of genetic algorithms are reviewed, include the schema theorem as well as recently developed exact models of the canonical genetic algorithms.
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The... more
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.
Dissolved organic carbon (DOC) in seawater is one of the largest reactive carbon reservoirs of carbon on earth. Estuaries show large gradients in DOC due to advective transport of terrestrial organic matter as well as high productivity,... more
Dissolved organic carbon (DOC) in seawater is one of the largest reactive carbon reservoirs of carbon on earth. Estuaries show large gradients in DOC due to advective transport of terrestrial organic matter as well as high productivity, but are complex regions for studying organic geochemical processes due to the intense mixing of waves, tides, and river inputs. Therefore, the sources and transformations of DOC in estuaries are not well understood. Although conservative mixing of riverine and marine waters has been suggested to control ...
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The... more
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.